Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612828 | 0.88 | NPC1 (0.43) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL30203055 | 0.82 | ELOVL1 (0.41) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL30203116 | 0.81 | NPC1 (0.47) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL23368156 | 0.81 | NPC1 (0.47) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL30203207 | 0.80 | NPC1 (0.41) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL28983497 | 0.79 | NPC1 (0.43) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL4328487 | 0.78 | NPC1 (0.45) | NPC1RAB9ATACR3MGLLPOLB | |
| SCHEMBL27668608 | 0.77 | NPC1 (0.44) | NPC1RAB9ATACR3MGLLPOLB | |
| SCHEMBL2635340 | 0.76 | RAB9A (0.54) | NPC1RAB9AHRH3TACR3MGLL | |
| SCHEMBL1727470 | 0.76 | NPC1 (0.47) | NPC1RAB9ATACR3MGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | NPC1 2118/4885RAB9A 667/4885HRH3 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.